Alterations of TIMP-3 Gene in Insulinomas and Its Significance Abstract #264

Introduction: Our previous study on insulinoma found allelic loss of 22q12 where suppressor gene TIMP3 located. TIMP3 can inhibit tumor invasion or metastasis, but its clinical implications in insulinoma are unknown.
Aim(s): To identify molecular alterations of TIMP-3 gene in insulinomas, and correlate gene alterations with the clinicalpathological features of insulinomas.
Materials and methods: TIMP-3 protein expression was detected in 68 insulinomas and 42 paired pancreatic tissues by IHC staining. Loss of heterozygosity (LOH) was measured by using PCR combined with autoradiography in 25 insulinomas. We correlated the experimental data with clinical-pathological characteristics. P value less than 0.05 was considered significant.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Dr Yuan-Jia Chen

To read results and conclusion, please login ...

Further abstracts you may be interested in

#72 Reduced expression of p27 and the occurrence of CpG island methylator phenotype in insulinomas
Introduction: The molecular pathogenesis of sporadic insulinoma is unclear, though some of the genes were found to be slienced by promoter methylation. CpG island methylator phenotype (CIMP) was found in a number of common tumors and correlated with loss of expression of p27, which may contribute to the tumorigenesis of the tumors.
Conference: 7th Annual ENETS Conference (2010)
Category: Basic
Presenting Author: Dr Yuan-Jia Chen
Authors: Chen Y J, Zhou Q, Xiao Y, Zhu Y, ...
#359 Expression of UCH-L1 in Pancreatic Endocrine Tumors and Its Clinical Significance
Introduction: Pancreatic endocrine tumors (PETs) are rare tumors with distinct clinical syndromes. There is a lack of reliable biomarker to distinguish benign and malignant form of PETs as well as to predict its prognosis. Our previous proteomic study on insulinoma found that overexpression of UCH-L1 in tumors. The diagnostic or prognostic value of this protein has not been well addressed in PETs.
Conference:
Category: Basic
Presenting Author: Prof Yuan-Jia Chen
Authors: Qiao X W, Wan Y H, Tang L, Lu C M, ...
#727 Serum Levels of Chromogranin A Were Not Elevated in Patients with Insulinomas
Introduction: According to ENETS and NANETS Consensus Guidelines, Chromogranin A (CgA) is the most practical and useful serum tumor marker in NET patients (pts), including pancreatic NETs. Many studies suggested that test of blood CgA should be mandatory for NET diagnosis.
Conference: 10th Annual ENETS Conference (2013)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: Dr. X-W Qiao
Authors: Qiao X W, Qiu L, Liu B, Song Y L, ...
#502 Bifunctional ShRNAimPDX-1 Therapy Prevents Hypoglycemic Death From Insulinoma in Mice
Introduction: PDX-1 is a novel molecular target for insulinoma. Bi-functional shRNAi platform has been developed that results in a more effective targeted gene knockdown.
Conference: 9th Annual ENETS Conference (2012)
Category: Basic
Presenting Author: Dr F Charles Brunicardi
Authors: Liu S, Wang Z, Shahi K, Rao D, ...
#2143 Efficacy and Safety of Anti-PD-1 Antibody (IBI308) in Treating Advanced Neuroendocrine Neoplams
Introduction: Neuroendocrine neoplasms (NENs) are a series of disease which show highly heterogeneity but have limited treatment options. Previous studies showed that tumor mutation burden (TMB) in NEC was relatively high which is considered as a predictive marker of anti-PD-1 antibody.
Conference: 15th Annual ENETS conference (2018)
Category: Medical treatment - others, not specified
Presenting Author: Ru Jia
Authors: Jia R, Li Y L, Jin Y S, Chen Y, ...